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Influenza A virus belongs to the family of Orthomyxoviridae. It is an enveloped virus with a
negative sense RNA segmented genome that encodes for 11 viral genes. This virus has
evolved a number of mechanisms that enable it to invade host cells and subvert the host cell
machinery for its own purpose, that is, for the sole production of more virus. Two of the
mechanisms that the virus uses are “cap-snatching” and preventing the host cell from ex-
pressing its own genes. This mini-review provides a brief overview as to how the virus is able
to invade host cells, replicate itself, and exit the host cell.
INTRODUCTION
Influenza A belongs to the family of
Orthomyxoviridae. It is an enveloped virus
with a genome made up of negative sense,
single-stranded, segmented RNA. The In-
fluenzaAviruses have eight segments that
encode for the 11 viral genes: hemagglu-
tinin (HA†), neuraminidase (NA), matrix 1
(M1), matrix 2 (M2), nucleoprotein (NP),
non-structural protein 1 (NSP1), non-struc-
tural protein 2 (NS2; also known as nuclear
export protein, NEP), polymerase acidic
protein (PA), polymerase basic protein 1
(PB1), polymerase basic protein 2 (PB2)
and polymerase basic protein 1 – F2 (PB1-
F2) [1].
The influenza virus virions are known
to display a number of shapes, with the
most abundant one being roughly spheri-
cal. The viral envelope is made up of a
lipid bilayer that contains three of the viral
transmembrane proteins: HA, NA, and
M2. This lipid bilayer is derived from the
host’s plasma membrane and is known to
contain both cholesterol-enriched lipid
rafts and non-raft lipids [2-4]. HA is the
most abundant envelope protein at approx-
imately 80 percent, followed by NA,
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viral envelope proteins. M2 is a very minor
component of the envelope, with only 16 to
20 molecules per virion. HAand NAare ex-
clusively associated with the lipid rafts in
the viral lipid membrane, whereas M2 is not
[4,5]. Sitting just underneath the viral lipid
membrane is M1, which forms a matrix
holding the viral ribonucleoproteins
(vRNPs). These vRNPs are the core of the
virus and are made up of the viral negative
stranded RNAs, which are wrapped up
around NPand very small amounts of NEP.
At one end of the vRNPs are the three poly-
merase (3P) proteins (PB1, PB2 and PA)
that make up the viral RNA polymerase
complex [1,4,6].
The influenza virus life cycle can be di-
vided into the following stages: entry into
the host cell; entry of vRNPs into the nu-
cleus; transcription and replication of the
viral genome; export of the vRNPs from the
nucleus; and assembly and budding at the
host cell plasma membrane. In this review,
each stage of the viral life cycle will briefly
be described.
ENTRY INTO THE HOST CELL
HA is a homotrimer that forms spikes
on the viral lipid membrane. These spikes
of HAbind to sialic acid found on the sur-
face of the host cell’s membrane [7]. The
HA precursor, HA0, is made up of two
subunits: HA1, which contains the recep-
tor binding domain, and HA2, which con-
tains the fusion peptide. These subunits
are linked by disulphide bonds [8]. Two
major linkages are found between sialic
acids and the carbohydrates they are
bound to in glycoproteins: α(2,3) and
α(2,6). These are extremely important for
the specificity of the HA molecules in
binding to cell surface sialic acid receptors
found in different species. Viruses from
humans recognize the α(2,6) linkage,
whereas those from avians and equines
recognize the α(2,3) linkages. Those from
swine recognize both [7]. This explains
the importance of swine being a good mix-
ing vessel for avian and human influenza
viruses, hence producing dangerous path-
ogenic viruses.
Upon binding to the host cell’s sialic
acid residues, receptor-mediated endocyto-
sis occurs and the virus enters the host cell in
an endosome. The endosome has a low pH
of around 5 to 6, which triggers the fusion
of the viral and endosomal membranes. The
low pH induces a conformational change in
HA0, leading to maintenance of the HA1 re-
ceptor-binding domain but exposing the
HA2 fusion peptide. This fusion peptide in-
serts itself into the endosomal membrane,
bringing both the viral and endosomal mem-
branes into contact with each other. Several
crystal structures of HA in its various con-
formations, i.e., at neutral and acid pH, have
been solved and are reviewed in [7] and [8].
The acidic environment of the endo-
some is not only important for inducing the
conformation in HA0 and, thus, fusion of
the viral and endosomal membranes but
also opens up the M2 ion channel. M2 is a
type III transmembrane protein that forms
tetramers, whose transmembrane domains
form a channel that acts as a proton-selec-
tive ion channel [9,10]. Opening the M2 ion
channels acidifies the viral core.This acidic
environment in the virion releases the vRNP
from M1 such that vRNPis free to enter the
host cell’s cytoplasm [11].
ENTRY OF vRNPs INTO
THE NUCLEUS
Influenza viral transcription and repli-
cation occurs in the nucleus; therefore, after
being released into the cytoplasm, the vRNP
must enter the nucleus. The viral proteins
that make up the vRNPare NP, PA, PB1, and
PB2. All of these proteins have known nu-
clear localization signals (NLSs) that can
bind to the cellular nuclear import machin-
ery and, thus, enter the nucleus.To date, it is
unclear which NLS is the most important for
vRNP nuclear entry. The different NLSs
present in each of these viral proteins are re-
viewed in [12]. It is known that import oc-
curs via the Crm1 dependent pathway by
binding to the various karyopherins in-
volved in nuclear import, for example, im-
portin α and β.
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REPLICATION OF THE VIRAL
GENOME
The influenza viral genome is made up
of negative sense strands of RNA. In order
for the genome to be transcribed, it first must
be converted into a positive sense RNA to
serve as a template for the production of
viral RNAs.
Replication of the genome does not re-
quire a primer; instead, the viral RNA de-
pendent RNA polymerase (RdRp) initiates
RNA synthesis internally on viral RNA.
This is possible, as the extreme 5’ and 3’
ends of the genome exhibit partial inverse
complementarity and, hence, are able to base
pair with one another to form various
corkscrew configurations. It appears that a
great number of di-nucleotide base pairs
form, although the full mechanism of viral
genome replication is still yet to be under-
stood [13-16].
Given that the influenza A virus only
encodes for 11 proteins, it has generated
many sophisticated methods of utilizing the
host cell’s machinery for its own purposes.
Through understanding viral transcription,
we have learned of a unique mechanism
whereby the virus hijacks the host’s tran-
scription machinery for its own benefits.
Mature cellular messenger RNAs
(mRNAs) have a 5’ methylated cap and a
poly(A)tail.ItisknownthatthevRNPshave
poly(A) tailsbutno 5’caps.Itwas confusing
when the influenza community discovered
that the viral mRNAs did have a 5’ methy-
lated cap and a poly(A) tail, but the 5’ cap
was not found in the viral genome [17,18].
Muchstudywentintothisproblem,andsoon
itwasdeterminedthatthe5’methylatedcaps
of the viral mRNAs actually belonged to the
cellular mRNAs. That discovery lead to the
formulation of the “cap-snatching” mecha-
nism [19-26]. The viral RdRp is made up of
three viral proteins: PB1, PB2, and PA. PB2
has endonuclease activity. It binds to the 5’
methylated caps of cellular mRNAs and
cleaves the cellular mRNAs’ 10 to 15 nu-
cleotides 3’to the cap structure.This cellular
capped RNA fragment is used by the viral
RdRp to prime viral transcription [27].
Cellular RNA Polymerase II (Pol II)
binds to DNA and starts transcription. Dur-
ing transcription initiation, serine 5 on the
C-terminal repeat domain (CTD) of Pol II is
phosphorylated, leading to the activation of
cellular cap synthesis complex. The in-
fluenza RdRp has been shown to bind pref-
erentially to this form of Pol II, indicating
that this could be the point at which “cap
snatching” could occur [28].
Six but two of the viral segments en-
code for one protein. Segments 7 and 8 en-
code for two proteins each due to splicing.
Segment 7 encodes for M1 and M2;
whereas, segment 8 encodes for NS1 and
NEP. M2 and NEP are the spliced products
and generally are found in much lower
abundance than NS1 and M1 [29].The virus
uses the host cell’s splicing machinery to ex-
press both of these proteins [30]. Despite in-
fluenza’s need for the cellular splicing
machinery, it prevents the host cell from
using its own splicing machinery for pro-
cessing the host cell mRNAs. NS1 binds to
U6 small nuclear RNAs (snRNAs) [31,32]
and other splicing components, causing
them to re-localize to the nucleus of infected
cells [33]. In this way, influenza is able to
inhibit splicing of cellular mRNAs. It also
has been shown to bind to a novel protein
called NS1 binding protein (NS1-BP), caus-
ing it to re-localize to the nucleus in infected
cells. The function of NS1-BP is unknown,
although it is predicted to be involved in
splicing given its co-localization with SC35,
a spliceosome assembly factor [34]. NPalso
has been shown to interact with UAP56, a
splicing factor involved in spliceosomal for-
mation and mRNAnuclear export, although
the importance of NP’s binding to UAP56 is
yet to be established [35].
The mechanism of polyadenylation of
viral mRNAs is very unusual. Cellular
mRNAs are polyadenylated through cleav-
age at the polyadenylation signal
(AAUAAA) by cleavage and polyadenyla-
tion specificity factor (CPSF) and subse-
quent addition of a poly(A) tail at the 3’end
of the mRNA. Viral mRNAs do not contain
this sequence; instead, the viral RdRp re-
mains bound to the 5’ end of the template
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end of viral RNA synthesis [36,37]. Each
viral segment has a stretch of five to seven U
residues approximately 17 nucleotides from
the 5’ end, and this forms the basis of the
viral polyadenylation signal [38].Therefore,
polyadenylation of the viral mRNAs occurs
due to a stuttering mechanism, whereby the
RdRp moves back and forth over this stretch
of U residues, leading to the formation of a
poly(A) tail [39,40]. Interestingly, NS1 in-
hibits the nuclear export of cellular mRNAs
by preventing cellular mRNAs from being
cleaved at the polyadenylation cleavage site
[41]. It does this by binding to the CPSF
[42] and poly(A) binding protein II
(PABPII), which is involved in stimulating
poly(A) polymerase to add the poly(A) tail
onto newly cleaved mRNAs [43].
EXPORT OF vRNPs FROM
THE NUCLEUS
It is known that only negative sense
vRNPs are exported from the nucleus [44].
vRNPs appear to be exported out of the nu-
cleus via the CRM1 dependent pathway
throughthenuclearpores.NPhasbeenshown
to interact with CRM1 directly, although no
GTP hydrolysis activity could be detected.
This indicates an unusual method of export if
the binding of NPto CRM1 is critical for ex-
port of the vRNPs. M1 is known to interact
directlywiththevRNPsthroughtheC-termi-
nalendoftheprotein.Interestingly,theN-ter-
minal portion of the protein is known to have
an NLS potentially involved in the import of
the vRNPs. It has been shown that the N-ter-
minal portion of M1 can bind to NEP, thus
masking the NLS. NEP also has been shown
tobindtoCRM1withtheaccompanyingGTP
hydrolysis that normally occurs in a CRM1-
dependentexportpathway.Therefore,itishy-
pothesisedthatM1bindstothenegativesense
vRNPs, as well as binding to NEP. In turn,
NEPbindstoCRM1,andthroughthis“daisy-
chain” complex, the vRNPs are exported out
of the nucleus [12,45,46].
Recently, live imaging has been em-
ployed to visualize the movement of vRNPs
during the influenza life cycle. It has been
shown that NPpreferentially localizes to the
apical side of infected nuclei, indicating po-
larized exit of the viral genome [47,48].
ASSEMBLY AND BUDDING AT THE
HOST CELL’S PLASMA MEMBRANE
After the vRNPs have left the nucleus,
all that is left for the virus to do is form viral
particles and leave the cell. Since influenza
is an enveloped virus, it uses the host cell’s
plasma membrane to form the viral particles
that leave the cell and go on to infect neigh-
bouring cells. It is possible to create virus
particles that do not contain any or only a
few vRNPs, but all the viral proteins nor-
mally found within the viral lipid bilayer,
i.e., HA, NA, and M2, must be present to
form a viral particle [4].
Virus particles bud from the apical side
of polarized cells [4]. Because of this, HA,
NA, and M2 are transported to the apical
plasma membrane. It has been shown
through deletion and mutational analysis
that the tail of M2 is extremely important in
the formation of viral particles. Viruses that
had the M2 tail deleted or partially mutated
produced elongated particles [49]. M1,
which is present underneath the lipid bilayer,
is important in the final step of closing and
budding off of the viral particle [6,50]. Sev-
eral host factors are involved in the budding
off of viruses from plasma membranes, and
these are reviewed in [4,51].
Therearetwomodelsthathavebeenhy-
pothesized to explain the packaging of viral
genomic segments into virions: the random
packaging model [52,53] and the specific
packaging model [54]. The former predicts
that viral genomic segments are randomly
packaged into virions; whereas, the latter
predicts that there are signals present in the
viral segments dictating which segments are
to be packaged into the virions. Packaging
signals have been identified in the 5’and 3’
non-coding and coding regions of some of
the viral segments [55-59], thus leaning to-
ward the specific packaging model.
One of the most important steps that
must occur before the newly made viral par-
ticle can leave the plasma membrane is the
cleavage of sialic acid residue from glyco-
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sialic acids. Without this process, the viral
particle would not be released from the
plasma membrane [60].
CONCLUSION
This is just a brief overview of the steps
in the influenzaAviral life cycle from entry
into a host cell to exit from the host cell.
This is a very complicated process, and there
is much still to be learned, such as the com-
plete mechanism of viral genomic RNA
replication. Like all viruses, influenzaAhas
evolved to take advantage of host cells by
processes such as “cap-snatching” and inhi-
bition of cellular mRNAsplicing and export.
Influenza A can be a deadly virus causing
many pandemics. We hope that by learning
how the virus is able to replicate in host
cells, we can develop better drugs and vac-
cines to protect us.
REFERENCES
1. Fields BN, Knipe DM, Howley PM. Fields
virology. Philadelphia: Wolters Kluwer
Health/LippincottWilliams &Wilkins; 2007.
2. Scheiffele P, Rietveld A, Wilk T, Simons K.
Influenza viruses select ordered lipid do-
mains during budding from the plasma mem-
brane. J Biol Chem. 1999;274(4):2038-44.
3. Zhang J, Pekosz A, Lamb RA. Influenza
virus assembly and lipid raft microdomains:
a role for the cytoplasmic tails of the spike
glycoproteins. JVirol. 2000;74(10):4634-44.
4. Nayak DP, Balogun RA, Yamada H, Zhou
ZH, Barman S. Influenza virus morphogene-
sis and budding.Virus Res. 2009;143(2):147-
61.
5. Schroeder C, Heider H, Moncke-Buchner E,
Lin TI. The influenza virus ion channel and
maturation cofactor M2 is a cholesterol-bind-
ing protein. Eur Biophys J. 2005;34(1):52-66.
6. Nayak DP, Hui EK, Barman S.Assembly and
budding of influenza virus. Virus Res.
2004;106(2):147-65.
7. Skehel JJ, Wiley DC. Receptor binding and
membrane fusion in virus entry: the influenza
hemagglutinin. Annu Rev Biochem.
2000;69:531-69.
8. Huang Q, Sivaramakrishna RP, Ludwig K,
KorteT, Bottcher C, HerrmannA. Early steps
of the conformational change of influenza
virus hemagglutinin to a fusion active state:
stability and energetics of the hemagglutinin.
Biochim BiophysActa. 2003;1614(1):3-13.
9. Holsinger LJ, Lamb RA. Influenza virus M2
integral membrane protein is a homotetramer
stabilized by formation of disulfide bonds.
Virology.1991;183(1):32-43.
10. Pinto LH, Holsinger LJ, Lamb RA. Influenza
virus M2 protein has ion channel activity.
Cell. 1992;69(3):517-28.
11. Pinto LH, Lamb RA. The M2 proton chan-
nels of influenza A and B viruses. J Biol
Chem. 2006;281(14):8997-9000.
12. Boulo S, Akarsu H, Ruigrok RW, Baudin F.
Nuclear traffic of influenza virus proteins and
ribonucleoprotein complexes. Virus Res.
2007;124(1-2):12-21.
13. Crow M, Deng T, Addley M, Brownlee GG.
Mutational analysis of the influenza virus
cRNA promoter and identification of nu-
cleotides critical for replication. J Virol.
2004;78(12):6263-70.
14. Deng T, Vreede FT, Brownlee GG. Different
de novo initiation strategies are used by in-
fluenza virus RNA polymerase on its cRNA
and viral RNA promoters during viral RNA
replication. J Virol. 2006;80(5):2337-48.
15. Flick R, Neumann G, Hoffmann E, Neumeier
E, Hobom G. Promoter elements in the in-






17. Plotch SJ, Tomasz J, Krug RM. Absence of
detectable capping and methylating enzymes
in influenza virions. J Virol. 1978;28(1):75-
83.
18. KrugRM,MorganMA,ShatkinAJ.Influenza
viral mRNA contains internal N6-methy-
ladenosineand5'-terminal7-methylguanosine
in cap structures. J Virol. 1976;20(1):45-53.
19. Dhar R, Chanock RM, Lai CJ. Nonviral
oligonucleotides at the 5' terminus of cyto-
plasmic influenza viral mRNAdeduced from
cloned complete genomic sequences. Cell.
1980;21(2):495-500.
20. Bouloy M, Plotch SJ, Krug RM. Globin
mRNAs are primers for the transcription of
influenza viral RNAin vitro. Proc NatlAcad
Sci USA. 1978;75(10):4886-90.
21. Plotch SJ, Bouloy M, Krug RM. Transfer of
5'-terminal cap of globin mRNAto influenza
viral complementary RNA during transcrip-




virion endonuclease cleaves capped RNAs to
generate the primers that initiate viral RNA
transcription. Cell.1981;23(3):847-58.
23. Bouloy M, Morgan MA, Shatkin AJ, Krug
RM. Cap and internal nucleotides of reovirus
mRNA primers are incorporated into in-
fluenza viral complementary RNA during
transcription in vitro. JVirol. 1979;32(3):895-
904.
24. Bouloy M, Plotch SJ, Krug RM. Both the 7-
methyl and the 2'-O-methyl groups in the cap
157 Samji: Influenza A: understanding the viral life cycleof mRNAstrongly influence its ability to act
as primer for influenza virus RNAtranscrip-
tion. Proc Natl Acad Sci USA.
1980;77(7):3952-6.
25. Krug RM, Broni BA, Bouloy M. Are the 5'
ends of influenza viral mRNAs synthesized
in vivo donated by host mRNAs? Cell.
1979;18(2):329-34.
26. Robertson HD, Dickson E, Plotch SJ, Krug
RM. Identification of the RNA region trans-
ferred from a representative primer, beta-glo-
bin mRNA, to influenza mRNA during in
vitro transcription. Nucleic Acids Res.
1980;8(5):925-42.
27. Li ML, Rao P, Krug RM. The active sites of
the influenza cap-dependent endonuclease
are on different polymerase subunits. EMBO
J. 2001;20(8):2078-86.
28. Engelhardt OG, Smith M, Fodor E.Associa-
tion of the influenzaAvirus RNA-dependent
RNA polymerase with cellular RNA poly-
merase II. J Virol. 2005;79(9):5812-8.
29. Amorim MJ, Digard P. InfluenzaAvirus and
the cell nucleus. Vaccine. 2006;24(44-
46):6651-5.
30. Engelhardt OG, Fodor E. Functional associ-
ation between viral and cellular transcription
during influenza virus infection. Rev Med
Virol. 2006;16(5):329-45.
31. LuY,QianXY,KrugRM.Theinfluenzavirus
NS1 protein: a novel inhibitor of pre-mRNA
splicing. Genes Dev. 1994;8(15):1817-28.
32. Wang W, Krug RM. U6atac snRNA, the
highly divergent counterpart of U6 snRNA,
is the specific target that mediates inhibition
ofAT-AC splicing by the influenza virus NS1
protein. RNA. 1998;4(1):55-64.
33. Fortes P, LamondAI, Ortin J. Influenza virus
NS1 protein alters the subnuclear localization
of cellular splicing components. J Gen Virol.
1995;76(Pt 4):1001-7.
34. Wolff T, O'Neill RE, Palese P. NS1-Binding
protein(NS1-BP):anovelhumanproteinthat
interacts with the influenzaAvirus nonstruc-
tural NS1 protein is relocalized in the nuclei
ofinfectedcells.JVirol.1998;72(9):7170-80.
35. Momose F, Basler CF, O'Neill RE, Iwamatsu
A, Palese P, Nagata K. Cellular splicing fac-
tor RAF-2p48/NPI-5/BAT1/UAP56 interacts
with the influenza virus nucleoprotein and
enhances viral RNA synthesis. J Virol.
2001;75(4):1899-908.
36. Fodor E, Pritlove DC, Brownlee GG. The in-
fluenzaviruspanhandleisinvolvedintheinitia-
tionoftranscription.JVirol.1994;68(6):4092-6.
37. Hagen M, Chung TD, Butcher JA, Krystal M.
Recombinant influenza virus polymerase: re-
quirementofboth5'and3'viralendsforendonu-
cleaseactivity.JVirol.1994;68(3):1509-15.
38. Robertson JS, Schubert M, Lazzarini RA.
Polyadenylation sites for influenza virus
mRNA. J Virol. 1981;38(1):157-63.
39. Poon LL, Fodor E, Brownlee GG. Polyuridy-
lated mRNA synthesized by a recombinant
influenza virus is defective in nuclear export.
J Virol. 2000;74(1):418-27.
40. Poon LL, Pritlove DC, Fodor E, Brownlee
GG. Direct evidence that the poly(A) tail of
influenzaAvirus mRNAis synthesized by re-
iterative copying of a U track in the virion
RNAtemplate. J Virol. 1999;73(4):3473-6.
41. Shimizu K, IguchiA, Gomyou R, OnoY. In-
fluenza virus inhibits cleavage of the HSP70
pre-mRNAs at the polyadenylation site. Vi-
rology. 1999;254(2):213-9.
42. Nemeroff ME, Barabino SM, LiY, KellerW,
Krug RM. Influenza virus NS1 protein inter-
acts with the cellular 30 kDa subunit of CPSF
and inhibits 3'end formation of cellular pre-
mRNAs. Mol Cell. 1998;1(7):991-1000.
43. Chen Z, Li Y, Krug RM. Influenza A virus
NS1 protein targets poly(A)-binding protein
II of the cellular 3'-end processing machinery.
EMBO J. 1999;18(8):2273-83.
44. Shapiro GI, Gurney T Jr., Krug RM. In-
fluenza virus gene expression: control mech-
anisms at early and late times of infection and
nuclear-cytoplasmic transport of virus-spe-
cific RNAs. J Virol. 1987;61(3):764-73.
45. Akarsu H, Burmeister WP, Petosa C, Petit I,
Muller CW, Ruigrok RW, Baudin F. Crystal
structure of the M1 protein-binding domain
oftheinfluenzaAvirusnuclearexportprotein
(NEP/NS2). EMBO J. 2003;22(18):4646-55.
46. Baudin F, Petit I, Weissenhorn W, Ruigrok
RW. In vitro dissection of the membrane and
RNPbinding activities of influenza virus M1
protein. Virology. 2001;281(1):102-8.
47. Loucaides EM, von Kirchbach JC, Foeglein
A, Sharps J, Fodor E, Digard P. Nuclear dy-
namics of influenza A virus ribonucleopro-
teins revealed by live-cell imaging studies.
Virology. 2009;394(1):154-63.
48. Elton D, Amorim MJ, Medcalf L, Digard P.
'Genome gating'; polarized intranuclear traf-
ficking of influenza virus RNPs. Biol Lett.
2005;1(2):113-7.
49. Iwatsuki-Horimoto K, Horimoto T, Noda T,
Kiso M, Maeda J, Watanabe S, et al. The cy-
toplasmic tail of the influenza A virus M2
protein plays a role in viral assembly. JVirol.
2006;80(11):5233-40.
50. Burleigh LM, Calder LJ, Skehel JJ, Stein-
hauer DA. Influenza a viruses with mutations
in the m1 helix six domain display a wide va-
riety of morphological phenotypes. J Virol.
2005;79(2):1262-70.
51. ChenBJ,LambRA.Mechanismsforenveloped





53. Bancroft CT, Parslow TG. Evidence for seg-
ment-nonspecific packaging of the influenza
a virus genome. JVirol. 2002;76(14):7133-9.
54. Smith GL, Hay AJ. Replication of the in-
fluenza virus genome. Virology.
1982;118(1):96-108.
158 Samji: Influenza A: understanding the viral life cycle55. Fujii Y, Goto H, Watanabe T, Yoshida T,
Kawaoka Y. Selective incorporation of in-
fluenza virus RNA segments into virions.
Proc NatlAcad Sci USA. 2003;100(4):2002-
7.
56. Muramoto Y, Takada A, Fujii K, Noda T,
Iwatsuki-Horimoto K, Watanabe S, et al. Hi-
erarchy among viral RNA(vRNA) segments
in their role in vRNA incorporation into in-
fluenza A virions. J Virol. 2006;80(5):2318-
25.
57. Watanabe T, Watanabe S, Noda T, Fujii Y,
KawaokaY.Exploitationofnucleicacidpack-
aging signals to generate a novel influenza
virus-based vector stably expressing two for-
eign genes. J Virol. 2003;77(19):10575-83.
58. Liang Y, Hong Y, Parslow TG. cis-Acting
packaging signals in the influenza virus PB1,
PB2, and PA genomic RNA segments. J
Virol. 2005;79(16):10348-55.
59. Fujii K, FujiiY, NodaT, MuramotoY,Watan-
abeT,TakadaA, et al. Importance of both the
coding and the segment-specific noncoding
regions of the influenza A virus NS segment
for its efficient incorporation into virions. J
Virol. 2005;79(6):3766-74.
60. Palese P, Tobita K, Ueda M, Compans RW.
Characterization of temperature sensitive in-
fluenza virus mutants defective in neu-
raminidase. Virology. 1974;61(2):397-410.
159 Samji: Influenza A: understanding the viral life cycle